贝伐珠单抗治疗糖尿病性黄斑水肿的疗效观察

J4 ›› 2016, Vol. 1 ›› Issue (4): 55-59.

贝伐珠单抗治疗糖尿病性黄斑水肿的疗效观察

（大理大学大理非直属附属医院，云南大理671000）

收稿日期:2015-09-22 出版日期:2016-04-15 发布日期:2016-04-15
作者简介:段直光，教授，主要从事玻璃体视网膜疾病和白内障研究.
基金资助:
大理州科技计划基金资助项目（20125）

Clinical Observation of Bevacizumab in the Treatment of Diabetic Macular Edema

（People's Hospital of Dali Prefecture, Dali, Yunnan 671000, China）

Received:2015-09-22 Online:2016-04-15 Published:2016-04-15

摘要/Abstract

摘要：

目的：评价玻璃体腔内注射贝伐珠单抗治疗糖尿病性黄斑水肿的临床效果与安全性。方法：对接受玻璃体腔注射Beva?
cizumab（1.75 mg）治疗的20例（26眼）糖尿病性黄斑水肿患者进行回顾性分析，对比分析治疗前后1、2、3、6月最佳矫正视力、
眼压、黄斑中心凹厚度变化。对所有病例进行6月以上的随访观察。结果：在20例（26眼）患者中平均年龄（57±18.56）岁。治
疗前患者的基线平均对数BCVA为（logMAR 0.82±0.63），CFT为（624.2±176.1）μm，注药后1周CFT没有显著改善，但BCVA有
显著提高，经平均随访9.8 mo，BCVA，CFT均较基线有显著改善，差异有统计学意义（P<0.01）。终末随访时BCVA提高≥两行
有22眼（84.6%），稳定2眼（7.7%）。本组患者共接受了92次玻璃体腔内注射，平均每眼注射次数为（3.98±1.52）次。结论：玻璃
体腔内注射bevacizumab可明显改善糖尿病黄斑水肿患者的视力，减轻黄斑水肿，减少CNV渗漏，重复治疗效果更佳。但远期
疗效尚须进一步观察。

关键词: 贝伐珠单抗（阿瓦斯汀）, 糖尿病视网膜病变, 黄斑水肿, 玻璃体腔注射

Abstract:

Objective: To evaluate the clinical effect and safety of intravitreal injection of bevacizumab in the treatment of diabetic
macular edema. Methods: The records of 26 eyes of 22 patients treated with intravitreal injection of 1.75mg bevacizumab for diabetic
macular edema were retrospectively analyzed. Best corrected visual acuity（BCVA）, intraocular pressure, choroidal leaks, central
retinal thickness（CFT） 1, 2, 3 months and 6 months before and after the treatment were analyzed and compared. Follow- up
observation were carried out among all cases after 6 months. Results: 26 eyes of 22 patients with the average of（57±18.56）years old
were included. The mean baseline of BCVA, CFT were（logMAR 0.82±0.63）,（624.2±176.1）μm respectively. Although there was no
significant decrease in mean CFT one week after the injection, the mean BCVA had significant improvement. At the last visit of 9.8
months' follow up, BCVA and CFT showed significant improvements over baseline values, which had a significant difference（P<
0.001）. BCVA was improved by at least two lines in 22 eyes（84.6%）, remained stable in 2 eyes（7.7%）at the last visit. A total of 92
injections were performed and the average number of injections was（3.98±1.52）in the group. Conclusion: Intravitreal injection of
bevacizumab can improve the visual acuity, reduce macular edema and choroidal leakage in patients with diabetic macular edema.
Repeated treatment has better effect, but a prolonged treatment effect needs further observation.

Key words: bevacizumab（avastin）, diabetic retinopathy, macular edema, intravitreal injection

中图分类号:

R774.1

段直光，贾云琴，莫逆，俞丽云，陈银朝，刘敏，蒲世雪，周霞. 贝伐珠单抗治疗糖尿病性黄斑水肿的疗效观察[J]. J4, 2016, 1(4): 55-59.

Duan Zhiguang, Jia Yunqin, Mo Ni, Yu Liyun, Chen Yingchao, Liu Min, Pu Shixue, Z. Clinical Observation of Bevacizumab in the Treatment of Diabetic Macular Edema[J]. J4, 2016, 1(4): 55-59.

参考文献

〔1〕NGUYEN Q D，SHAH S M，VAN ANDEN E，et al. Supple?
mental oxygen improves diabetic macular edema：a pilot
study〔J〕. Invest Ophthalmol Vis Sci，2004，45：617-624.
〔2〕FERRARA N. Vascular endothelial growth factor：basic sci?
ence and clinical progress〔J〕. Endocr Rev，2004，25：581-
611.
〔3〕VALMAGGIA C，HAUETER I，KLOOS P，et al. The treat?
ment of choroidal neovascularizations in age-related macu?
lar degeneration using either Avastin or Lucentis〔J〕. Klin
Monatsbl Augenheilkd，2009，226（4）：294-298.
〔4〕于同利，毕宏生. Avastin 在眼科应用的研究进展〔J〕.
国际眼科杂志，2008，8（4）：810-812.
〔5〕STEWART M W. The expanding mle of vascular endotheli?
al growth factor inhibitors in ophthalmology〔J〕. Mayo Clin
Proc，2012，87：77-88．
〔6〕TERUI T，KONDO M，SUGITA T，et al.Changes in areas of
capillary nonperfusion after intravitreal injection of beva?
cizumab in eyes with branch retinal vein occlusion〔J〕.
Retina，2011，31：1068-1074．
〔7〕THAPA R，POUDYA J G. Short term results of intravitreal
bevacizumab for the treatment of macular edema secondary
to retinal vein occIusion〔J〕. Nepal J Ophthalmol，2013，5：
63-68.
〔8〕EPSTEIN D I，ALGVERE P V，VON WENDT G，et al.
Bevacizumab for macular edema in central retinal vein oc?
clusion：a prospective，randomized，double-masked clinical
study〔J〕. Ophthalmology，2012，119：1184-1189．

〔9〕MARNEROS A G，FAN J，YOKOYAMA Y，et al. Vascular
endothelial growth factor expression in the retinal pigment
epithelium is essential for choricapillaris development and
visualfunction.Am〔J〕.Ophthalmol，2005，167：1451-1459.
〔10〕SIEGEL R A，DREZNIK A，MB K，et al. Intravitreal Beva?
cizumab Treatment for Macular Edema due to Branch Ret?
inal Vein occlusion in a Clinical Setting〔J〕. Curr Eye Res，
2012，37：823-829．
〔11〕AREVALO J F，FROMOW-GUERRA J，QUIROZ-MERE?
ADO H，et al. Primary intravitreal bevaeizumab（Avastin）
for diabetic macular edema：results from the Pan-Ameri?
can Collaborative Retina Study Group at 6-month fol?
low-up〔J〕. Ophthalmology，2007，114：743-750.
〔12〕SOLIMAN W，VINTEN M，SANDER B，et al. Optical co?
herence tomography and vessel diameter changes after in?
travitreal bevacizumab in diabetic macular edema〔J〕. Ae?
ta Ophthalmol Scand，2007，85：765-771.
〔13〕HARITOGLOU C，KOOK D，NEUBAUER A，et al. Intra?
vitreal bevacizumab（Avastin）therapy for persistent diffuse
diabetic macular edema〔J〕. Retina，2006，26：999-1005.
〔14〕段直光，贾云琴，莫逆，等. Bevacizumab治疗视网膜静
脉阻塞继发黄斑水肿的临床观察〔J〕. 国际眼科杂志，
2014，14（9）：1594-1598.
〔15〕CHAN A，DUKER J S. A standardized method for report?
ing changes in macular thickening using optical coherence
tomography〔J〕. Arch Ophthalmol，2005，123：939-943.